Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by BioSpectrum Asia discussing the development of the company’s cell-based immunotherapies for cancer treatment. The article discusses:

• The advantages of using iPSCs from cord blood for creating ‘off-the-shelf’ CAR-NK and CAR-T therapies.
• How Cartherics’ lead product, CTH-401 differentiates itself as the only NK cell product developed specifically to target TAG-72, with unique modifications to enhance immune cell efficacy.
• The company’s pipeline, therapeutic areas to target and future plans
• How current trends in CGT are shaping the future of cancer immunotherapies

Read the article here: https://www.biospectrumasia.com/opinion/98/25131/moving-forward-cancer-may-not-be-a-death-threat-but-a-manageable-disease-with-strong-control.html